With 93 percent of patients with relapsed or refractory acute lymphoblastic leukemia (ALL) achieving complete initial remission in their PLAT-02 trial, researchers at Seattle Children’s are continuing to improve the experimental immunotherapy and reduce the rate of relapse.
Regulators have voted to approve America's first ever gene therapy for public use. An advisory panel of cancer experts at the Food and Drug Administration unanimously backed the one-time treatment at a meeting on Wednesday.
When I came to Seattle Children’s in 2010, my vision was for us to become a global epicenter for childhood cancer immunotherapy cures. I imagined that, someday, doctors from around the world would send us blood cells from children with cancer. We would insert instructions into T cells – a “warrior” type of immune cell – that tell them to find and kill cancer cells. Then we would send the “reprogrammed” cells back to the hospital, where the child would receive them as a simple infusion.